Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
Clinigen's planned purchase of US rights to Proleukin will give it global ownership of the IL-2 drug.
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.
EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.
UK's Grey Wolf Therapeutics completes £10m Series A financing for use in altering tumor cells, illuminating them for attack and destruction by the immune system.